cjc-1295/ipamorelin peptides CJC-1295 + Ipamorelin | GH Peptide Therapy CJC-1295 & Ipamorelin Blend For

Scientific Background Growth hormone release is regulated through complex endocrine signaling involving hypothalamic and pituitary pathways

Consider complementary supplements like melatonin (low dose), NAD+ precursors, or antioxidants

Ipamorelin vs GHRP-2 and GHRP-6 GHRP Family Side-by-Side Feature Receptor Ipamorelin GHS-R1a GHRP-2 GHS-R1a GHRP-6 GHS-R1a Feature Half-life Ipamorelin ~2 hours GHRP-2 ~25-30 minutes GHRP-6 ~20-30 minutes Feature Dosing Ipamorelin 1-3x daily (SubQ) GHRP-2 2-3x daily (SubQ) GHRP-6 2-3x daily (SubQ) Feature Standard dose Ipamorelin 100-300 mcg GHRP-2 100-300 mcg GHRP-6 100-300 mcg Feature Cortisol effect Ipamorelin None at standard doses GHRP-2 Yes GHRP-6 Yes Feature Prolactin effect Ipamorelin None GHRP-2 Moderate GHRP-6 Minimal Feature Appetite effect Ipamorelin Mild GHRP-2 Moderate GHRP-6 Strong Feature FDA status Ipamorelin Not approved GHRP-2 Not approved GHRP-6 Not approved All three target the same receptor

The Case for Sermorelin: When the Gentler Approach Fits Despite being the oldest compound in the sermorelin vs CJC-1295 vs ipamorelin comparison, sermorelin retains clear research advantages in specific contexts